WO2021224947A1 - Formulation d'une formulation de lutte contre une maladie respiratoire aiguë - Google Patents

Formulation d'une formulation de lutte contre une maladie respiratoire aiguë Download PDF

Info

Publication number
WO2021224947A1
WO2021224947A1 PCT/IR2020/050022 IR2020050022W WO2021224947A1 WO 2021224947 A1 WO2021224947 A1 WO 2021224947A1 IR 2020050022 W IR2020050022 W IR 2020050022W WO 2021224947 A1 WO2021224947 A1 WO 2021224947A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
herbal
covid
effects
acute respiratory
Prior art date
Application number
PCT/IR2020/050022
Other languages
English (en)
Inventor
Mehdi NOROUZI
Majid LA'L ROSHAN
Hassan SHADEMANI
Original Assignee
Norouzi Mehdi
Lal Roshan Majid
Shademani Hassan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norouzi Mehdi, Lal Roshan Majid, Shademani Hassan filed Critical Norouzi Mehdi
Publication of WO2021224947A1 publication Critical patent/WO2021224947A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives

Definitions

  • [COVID-19 belongs to the Coronaviridae family (CoV), ssRNA + viruses, which are widely distributed among humans and other mammals and cause a wide range of infections, from cold symptoms to fatal respiratory diseases.
  • the virus is also zoonotic and can be transmitted between humans and animals.
  • the death rate of this new CoV in China is about 2%, which is lower than the mortality of SARS and MERS.
  • Common symptoms of infection include respiratory symptoms, fever, cough, shortness of breath. In more severe cases, the infection can cause pneumonia, acute respiratory syndrome, kidney failure, and even death. These symptoms may appear 2-14 days after exposure to the virus. So far, no specific or FDA-approved treatment for COVID-19 infection has been approved.
  • Coronaviruses are RNA viruses that are widely spread among humans, other mammals, and birds and cause respiratory, intestinal, liver, and neurological diseases.
  • the four viruses 229 E, OC43, NL63, and HKU1 are very common and usually cause cold symptoms in people with defective immune systems.
  • Two other species - Acute Respiratory Coronavirus (SARS-CoV) and Middle East Respiratory Coronavirus (MERS-CoV) are zoonotic and have been linked to fatal diseases.
  • the herbal formulation contains many phytochemicals and active ingredients with antiviral effects that have been repeatedly demonstrated in previous studies.
  • Garlic In today's medicine, various studies have been conducted on garlic and its antimicrobial and antiviral effects. In one study, it was used as a preventative factor against colds in 146 people as a sample, and the study found that people who took allicin supplements were less likely to catch colds during the study period. In another study on the embryo of a chicken, its antiviral effects on the influenza virus H9N2 were proven. Another study on the antiviral properties of garlic extract found that garlic have the inhibitory properties against the influenza A virus (H1N1) pdm09 by inhibiting the synthesis of the virus's nucleoprotein and its polymerase activity.
  • Fennel The antiviral effects of the essential oil and extract of this plant have been reported in several studies.
  • Savory It has antimicrobial, antifungal, anti-inflammatory and anti-viral properties.
  • Golpar It is a plant with a warm nature and its chemical compounds include methyl butyrate, acetate ethyl butyrate, acethyl acetate hexhyl and some other acids. In traditional medicine, this plant is used as a remedy for bloating, indigestion, appetizing, stomach tonic, antimicrobial and antiseptic. In addition, it has antibacterial, antifungal and antioxidant effects.
  • Thyme Shirazi The effects of thyme against Herpes simplex type 1 have been proven in all stages of the disease.
  • the phenolic compounds in thyme, such as thymol and carvacrol prevent viral replication by inhibiting protein synthesis, or RNA, and limit the entry of the virus into host cells by disrupting haemaglutinin activity.
  • thyme extract improved FEV1, and the rate of wheezing and plasma levels of N02 was reduced in these patients.
  • thyme extract reduced the expression of the gene for inflammatory cytokines (IL-4, IL- 17, TGF-b) and increased anti-inflammatory cytokines (IFN-y) and FOXP3 in splenocytes and suppressed Th2 and Thl7 cells in mice.
  • IL-4 inflammatory cytokines
  • IFN-y anti-inflammatory cytokines
  • FOXP3 FOXP3
  • Clove Groups of phenolic and alkamide compounds have been shown to have antiviral and antifungal properties, respectively, which can prevent or control upper respiratory tract infections (URIs).
  • URIs upper respiratory tract infections
  • its strong antiviral activity has been attributed to several viruses, including type IV H3N2. It also effectively reverses the inflammatory responses caused by the virus in cultured epithelial cells.
  • recent studies have shown that the preparation of the extract at non-toxic concentrations of certain species and parts of the plant has potent antiviral activity, especially against membrane-containing viruses.
  • all human influenza viruses including Tamiflu-resistant strains), as well as herpes simplex virus, respiratory viruses, and rhinoviruses, were highly sensitive to the standard Akinase extract.
  • Opium Provides ample evidence of drug use to treat acute and chronic pain. Flowever, the doctor must consider the risks of abuse and dependence and its side effects when using the opioids. These compounds have long been used as sedatives and painkillers. Since the nineteenth century, with the separation of opium alkaloids and the administration of these substances, their medical use has increased. Various pharmaceutical groups of opioids are still the strongest painkillers, although their effectiveness has been questioned for some types of pain.]
  • ingredients of the syrup consisting of plants: Shirazi thyme with the scientific name of Zataria multiflora Boiss., Garlic with the scientific name of Alium Sativum., Angelica with the scientific name of Fleracleum persicum Foeniculum vulgare and opium.
  • Syrup preparation Compared to the total weight of the syrup, 50% of the extracts of the mentioned plants were mixed with 20% of honey and after some time of continuous mixing at room temperature, it was adjusted to specific with pure water. Filling operations were performed on 120 ml bottles, (labeling and jet printing of syrup ) Figure 1-2 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'apparition de l'épidémie de la covid-19 en 2020 qui est devenue une préoccupation globale nous a conduit à développer un médicament contre le coronavirus en coopération avec des experts médicaux pour traiter des patients hospitalisés. Des formulations d'origine végétale présentant des effets antiviraux à large spectre ont été produites pour la première fois et ont été envoyées à des centres médicaux pour effectuer des essais cliniques. Le dépôt du brevet de cette formulation d'origine végétale semble nécessaire pour prévenir et lutter contre la covid-19. Selon des études précédentes, chacun des constituants d'origine végétale de la formulation présente des effets antiviraux et antitussifs significatifs. Les formulations d'origine végétale contiennent de l'ail, du fenouil, de la sarriette, de la berce de Perse, des thyms, du girofle et de l'opium qui ont des effets antiviraux et qui améliorent les systèmes immunitaire et respiratoire. Après analyse des données des essais, il a été constaté que la plupart des patients ont vu leur état s'améliorer après la prise de ce médicament et l'atteinte des poumons et d'autres organes s'est rapidement améliorée.
PCT/IR2020/050022 2020-05-02 2020-07-17 Formulation d'une formulation de lutte contre une maladie respiratoire aiguë WO2021224947A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IR139950140003001041 2020-05-02
IR13993001040 2020-05-02

Publications (1)

Publication Number Publication Date
WO2021224947A1 true WO2021224947A1 (fr) 2021-11-11

Family

ID=78468767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IR2020/050022 WO2021224947A1 (fr) 2020-05-02 2020-07-17 Formulation d'une formulation de lutte contre une maladie respiratoire aiguë

Country Status (1)

Country Link
WO (1) WO2021224947A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009245A1 (en) * 2000-04-03 2004-01-15 Vail William Banning Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
WO2011117424A1 (fr) * 2010-03-26 2011-09-29 Cesa Alliance S.A. Compositions inhibitrices virales pour une utilisation thérapeutique in vivo comprenant une combinaison de (-)-carvone, de géraniol et d'un autre composant d'huile essentielle

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009245A1 (en) * 2000-04-03 2004-01-15 Vail William Banning Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
WO2011117424A1 (fr) * 2010-03-26 2011-09-29 Cesa Alliance S.A. Compositions inhibitrices virales pour une utilisation thérapeutique in vivo comprenant une combinaison de (-)-carvone, de géraniol et d'un autre composant d'huile essentielle

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Will Clove Oil Help In Combating COVID-19?", 30 March 2020 (2020-03-30), XP002801599, Retrieved from the Internet <URL:https://english.sakshi.com/wellness/2020/03/30/will-clove-oil-help-in-combating-covid-19> [retrieved on 20210112] *
GYÖRGYI HORVATH ET AL: "Essential oils in the treatment of respiratory tract diseases highlighting their role in bacterial infections and their anti-inflammatory action: a review : Essential oils in the treatment of respiratory tract diseases", FLAVOUR AND FRAGRANCE JOURNAL., vol. 30, no. 5, 26 May 2015 (2015-05-26), GB, pages 331 - 341, XP055391769, ISSN: 0882-5734, DOI: 10.1002/ffj.3252 *
KULKARNI SEEMA A ET AL: "Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein", JOURNAL OF MOLECULAR STRUCTURE, ELSEVIER AMSTERDAM, NL, vol. 1221, 4 July 2020 (2020-07-04), XP086367096, ISSN: 0022-2860, [retrieved on 20200704], DOI: 10.1016/J.MOLSTRUC.2020.128823 *
MOTAHAREH ROUHI ARDESHIRI: "Evaluating efficacy and safety of Stopcivir (Zataria multiflora Boiss+ Alium Sativum+ Heracleum persicum+ Satureja hortensis+ Dianthus+ Foeniculum vulgare+ opium) syrup on length of hospitalization in patients with COVID-19", 31 May 2020 (2020-05-31), XP002801600, Retrieved from the Internet <URL:https://en.irct.ir/trial/47044> [retrieved on 20210111] *
SHOJAI T M ET AL: "The effect of Allium sativum (garlic) extract on infectious bronchitis virus in specific pathogen free embryonic egg", AVICENNA JOURNAL OF PHYTOMEDICINE 20160601 MASHHAD UNIVERSITY OF MEDICAL SCIENCES IRN, vol. 6, no. 4, 1 June 2016 (2016-06-01), pages 458 - 467, XP009524855, ISSN: 2228-7930 *
TEPE B: "Inhibitory effect of Satureja on certain types of organisms", RECORDS OF NATURAL PRODUCTS 2015 ACG PUBLICATIONS TUR, vol. 9, no. 1, 2015, pages 1 - 18, XP009524854, ISSN: 1307-6167 *

Similar Documents

Publication Publication Date Title
Hensel et al. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature
Naser et al. Thuja occidentalis (Arbor vitae): a review of its pharmaceutical, pharmacological and clinical properties
Ge et al. Anti-influenza agents from traditional Chinese medicine
El Sayed et al. Promising preventive and therapeutic effects of TaibUVID nutritional supplements for COVID-19 pandemic: towards better public prophylaxis and treatment (A retrospective study)
Gajewski et al. Potential of herbal products in prevention and treatment of COVID-19. Literature review
Singh et al. Shikimic acid as intermediary model for the production of drugs effective against influenza virus
WO2022050516A1 (fr) Agent thérapeutique contre le coronavirus comprenant un extrait d&#39;elaeocarpus sylvestris en tant que principe actif
CN101797246B (zh) 黄芩黄酮抗甲型流感病毒亚型感染的应用
CN113855654B (zh) 一种预防和治疗冠状病毒感染的组合物
Ricci et al. Exploring the Protective Effect of Food Drugs against Viral Diseases: Interaction of Functional Food Ingredients and SARS-CoV-2, Influenza Virus, and HSV
Yedjou et al. Pharmacological effects of selected medicinal plants and vitamins against COVID-19
CN111789880A (zh) 肉桂提取物在抑制covid-19新型冠状病毒进入细胞及复制中的应用
EP2490703B1 (fr) Composition à base d&#39;herbe médicinale comprenant du gingembre et de la verge d&#39;or pour le traitement d&#39;une infection d&#39;influenza
US9616124B2 (en) Antiviral supplement compositions and methods of use
WO2020208659A1 (fr) Composition d&#39;immunostimulation antibactérienne et antivirale d&#39;extraits d&#39;herbes dans des rapports synergiques
WO2021224947A1 (fr) Formulation d&#39;une formulation de lutte contre une maladie respiratoire aiguë
Dziewiatkowski et al. Baloxavir: A novel single-dose oral antiviral for the treatment of influenza
Vats et al. Prediction of anti-viral activity of Ipomoea carnea
Vicentini et al. Ancient treatment for lice: a source of suggestions for carriers of other infectious diseases?
Kamalinejad et al. The Clinical Efficacy of Tiban Syrup as Adjuvant Treatment in Patients with COVID-19: A Randomized, Double-Blind Clinical Trial: The clinical efficacy of Tiban syrup on COVID-19
Pal et al. A Brief Outlook on Possible Available Solutions, Therapies and Suggestions for COVID-19
Lee et al. Flu for you? The common cold, influenza, and traditional medicine
Munishwar et al. COVID-19: opportunity for mainstreaming Ayurveda to transform Indian health care
Teymoori Evaluation of the effects of peppermint on improving the function of the respiratory system in COVID-19 infection
CA2846513C (fr) Composition antioxydante antigrippale naturelle

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20765372

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20765372

Country of ref document: EP

Kind code of ref document: A1